CRIS Current Research Information System

ROBUSTELLI, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.903
EU - Europa 1.556
AS - Asia 692
AF - Africa 138
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
SA - Sud America 3
Totale 4.300
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.897
GB - Regno Unito 450
VN - Vietnam 347
SE - Svezia 272
IT - Italia 242
DE - Germania 190
CN - Cina 187
IN - India 96
IE - Irlanda 73
CH - Svizzera 67
FR - Francia 64
TG - Togo 49
RU - Federazione Russa 43
BG - Bulgaria 36
ZA - Sudafrica 36
EE - Estonia 34
JO - Giordania 28
CI - Costa d'Avorio 27
NG - Nigeria 26
UA - Ucraina 23
BE - Belgio 22
FI - Finlandia 14
JP - Giappone 10
IR - Iran 8
GR - Grecia 7
UZ - Uzbekistan 7
CA - Canada 6
NL - Olanda 6
PL - Polonia 4
AU - Australia 3
EU - Europa 3
AT - Austria 2
BD - Bangladesh 2
BR - Brasile 2
CZ - Repubblica Ceca 2
HK - Hong Kong 2
MK - Macedonia 2
TR - Turchia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CL - Cile 1
HR - Croazia 1
IL - Israele 1
KR - Corea 1
LU - Lussemburgo 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
TM - Turkmenistan 1
Totale 4.300
Salva come PNG Salva come JPEG
Città #
Southend 427
Chandler 314
Dong Ket 235
Ashburn 166
Fairfield 164
Ann Arbor 117
Houston 110
Woodbridge 98
Wilmington 85
Princeton 82
Seattle 78
Dublin 73
Cambridge 64
Bern 58
Beijing 51
Lomé 49
Bologna 48
Westminster 37
Nanjing 36
Sofia 36
Padova 33
Medford 32
Amman 28
Abidjan 27
New York 27
Abeokuta 26
Bremen 26
Boardman 23
Redmond 23
Berlin 22
Brussels 21
Redwood City 18
Saint Petersburg 15
Helsinki 14
Paris 14
Nanchang 13
Hebei 11
Mountain View 11
Florence 10
Jinan 10
Shenyang 10
Changsha 9
Falls Church 9
Milan 9
Rome 9
San Diego 8
Monmouth Junction 7
Turin 7
Augusta 6
Norwalk 6
Pune 6
Tokyo 6
Andover 5
Forlì 5
Hangzhou 5
Jiaxing 5
Leawood 5
Tianjin 5
Athens 4
Des Moines 4
Fremont 4
Guangzhou 4
Busseto 3
Bühl 3
Castel Madama 3
Dearborn 3
Dehradun 3
Haikou 3
Henderson 3
Los Angeles 3
Reggio Emilia 3
Taiyuan 3
Torino 3
Vellore 3
Zhengzhou 3
Alpharetta 2
Avellino 2
Bitola 2
Ceska 2
Chesterfield 2
Den Haag 2
Dhaka 2
Frankfurt Am Main 2
Groningen 2
Hyderabad 2
Kiev 2
Kilburn 2
Latina 2
Lausanne 2
London 2
Malvern 2
Miradolo Terme 2
Olalla 2
Phoenix 2
Sacramento 2
San Lazzaro di Savena 2
São Paulo 2
Taizhou 2
Toronto 2
Vasto 2
Totale 2.959
Salva come PNG Salva come JPEG
Nome #
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 218
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 180
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 180
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 177
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 173
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 154
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 145
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 134
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 130
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 122
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 121
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 119
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 116
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 116
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 113
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 110
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 109
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 105
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 105
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 103
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 98
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 96
Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia 96
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 95
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 93
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 93
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 87
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 86
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET 84
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 83
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 82
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 80
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 79
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 79
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 78
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 77
You have accessMine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs 71
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 64
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 61
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 49
Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia 47
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 28
Totale 4.436
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.421
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.421
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201971 0 0 0 0 0 0 0 0 0 0 24 47
2019/2020847 147 44 0 42 80 57 90 107 105 82 64 29
2020/2021770 94 76 36 8 24 31 7 45 62 16 45 326
2021/2022954 122 24 43 88 93 43 13 66 35 61 190 176
2022/20231.177 126 160 60 158 103 89 29 51 197 33 80 91
2023/2024290 10 36 22 37 24 80 19 40 12 10 0 0
Totale 4.436